Physician profile
Warren E Frick
NPI 1609880863
$1,329.77
in general payments reported to CMS, 2019-2025
19 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $18.22 · 2021: $83.90 · 2022: $440 · 2023: $304 · 2024: $228 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $260.28 | 2019-2025 | Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $181.37 | 2021-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $179.77 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $140.50 | 2022-2025 | Dupixent |
| Optinose US, INC. | $96.00 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $73.05 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.12 | 2023-2025 | Takhzyro, Eohilia |
| Covis Pharma Gmbh | $43.46 | 2022 | |
| Hikma Pharmaceuticals USA | $35.02 | 2023 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $33.00 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $31.20 | 2022 | |
| Merck Sharp & Dohme LLC | $29.86 | 2021 | |
| Genentech USA, INC. | $25.67 | 2024 | Xolair |
| Pharming Healthcare, INC. | $25.21 | 2019-2023 | Ruconest |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $25.00 | 2021 | |
| Kaleo, INC. | $17.04 | 2022 | |
| Grifols USA, LLC | $16.75 | 2023 | Prolastin-C Liquid |
| Abbvie INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Frick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.